Sagimet Biosciences Inc. (SGMT) stock
SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.85−0.28 (-2.76%)
Close on Nov 17, 2026Market cap $612.26MP/E –Yield –
Sagimet Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Sagimet Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$41.72M. For fiscal 2025 it was -$45.65M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$45.65M | – |
| FY2024 | Dec 31, 2024 | -$42.44M | – |
| FY2023 | Dec 31, 2023 | -$23.77M | – |
| FY2022 | Dec 31, 2022 | -$24.49M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$11.10M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.61M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.83M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.18M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.10M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.54M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.02M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.57M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.63M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.21M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.08M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.88M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.72M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.08M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.45M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.23M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.00K | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.80M | – |
See a number that looks wrong?